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The M protein of group A streptococci is an a-helical coiled-coil molecule (1) that
projects from the surface of these organisms and functions as the major virulence
factor (2) . Only antibodies directed against these structures are protective against
subsequent infections (2). Vaccine development has been hampered by the finding
that some M protein molecules contain tissue-crossreactive epitopes in addition to
protective epitopes (3-8). Previous studies (9-11) have shown that protective M pro-
tein epitopes could be separated from tissue-crossreactiveepitopes by using synthetic
peptides copying limited regions of the NH2 terminus of the native M protein
molecules. For example, type 5 M protein evokes both protective and heart-
crossreactive antibodies, and some of the heart-crossreactive antibodies also react
with the heterologous types 6 and 19 M proteins (5) . Synthetic peptides representing
the NH2-terminal 20 amino acids of type 5 (9) and type 6 (11) M proteins evoke
type-specific, opsonic antibodies that are not heart crossreactive. These findings have
suggested that the heart-crossreactive epitopes of M proteins might be avoided by
using only the NH2-terminal primary structures as vaccine components. To test the
generality ofthis hypothesis, we decided to examine additional"rheumatogenic" sero-
types of M protein.
In the present study, we investigated the protective and autoimmune epitopes of
type 19 streptococcal M protein. We show that a purified pepsin extract of type 19
streptococci (pep M19) evokes not only opsonic antibodies, but also heart-crossreactive
antibodies in rabbits. By using a combination of synthetic peptides and pep M19,
we further show that autoimmune epitopes may be located within the NH2-terminal
regions of certain M protein molecules. Thus, the concept that protective epitopes
can always be separated from autoimmune epitopes by focusing on the NH2-
terminal regions of the various M protein serotypes must be reevaluated.
Volume 167 June 1988 1849-1859
Materials and Methods
Extraction and Purification ofM Proteins.
￿
Type 19 M protein was extracted from intact type
19 group A streptococci by limited pepsin digestion at pH 5.8, and was purified by ammo-
nium sulfate precipitation and ion-exchange chromatography as previously described (12) .
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Pep M19 was further purified by electroelution of the 43-kD polypeptide from SDS-
polyacrylamide slab gels. 1 mg of pep M19 was added to each offour gels and electrophoresed
under reducing conditions. Each gel was briefly stained with Coomassie blue and destained
overnight in an aqueous solution containing 10% methanol and 7.5% acetic acid. After washing
the gels in distilled water, proteins with an apparent molecular weight of 43 x 103 were cut
from the gels and placed in dialysis tubing (Spectrum Medical Industries, Inc., Los Angeles,
CA) containing 0.003 M trizmabase, 0.02 M glycine, 20% methanol, pH 8.3 (transphor buffer).
The proteins were electroeluted from the gels in a transphor electrophoresis unit (Hoeffer
Scientific Instruments, San Francisco, CA) at 2°C with a current 0.9 mA for 4 h. The elec-
troeluted proteins were dialyzed overnight against distilled H2O at 4°C and then were lyophi-
lized. Coomassie blue stain and residual salt were removed by applying the preparation to
a Bio-Gel P6 molecular sieve column (Bio-Rad Laboratories, Richmond, CA) equilibrated
with 2.5 M guanidine/HC1/0.05% Tris, pH 7 .4. The column fractions representing the ini-
tial peak of the chromatogram (OD23o) were collected and pooled, dialyzed overnight in dis-
tilled water, and then lyophilized. The SDS was removed by resuspending the product in
1 ml of 1 M acetic acid, adding three drops of proprionic acid, and applying it to a Bio-Gel
P2 molecular sieve column (Bio-Rad Laboratories, Richmond, CA) equilibrated with 0.1
M acetic acid. The initial peak of the chromatogram (OD230) was collected, dialyzed over-
night in distilled water, and lyophilized. The protein was judged to be homogeneous by
SDS-PAGE.
Determination of the NH2-Terminal Primary Structure ofpep M19.
￿
The NH2-terminal amino
acid sequence of the purified pep M19 was determined by automated Edman degradation,
as previously described (13, 14) .
Chemical Synthesis of SM19(1-24)C.
￿
A peptide copying the NH2-terminal 24-amino acid
residues ofpep M19 was chemically synthesized by an automated peptide synthesizer as reported
(10, 14), and is designated SM19(1-24)C. Additionally, two overlapping subpeptides of
SM19(1-24)C were synthesized and designated as SM19(1-14)C and SM19(11-24)C, respec-
tively. The sequence ofeach synthetic peptide was confirmed by automated Edman degrada-
tion to the penultimate residues (14, 15).
Immunization Procedures.
￿
New Zealand White rabbits were immunized subcutaneously with
100 gg of pep M19 emulsified in CFA (12). Booster injections consisting of the same dose
in 0.02 M phosphate/0.15 M NaCI, pH 7.4 (PBS) were given at 4 and 8 wk. Serum was ob-
tained before the initial injection and at 2-wk intervals thereafter. Rabbits were immunized
with 300 wg of SM19(1-24)C emulsified in CFA. Booster injections of the same dose in PBS
were given and serum was obtained as described above.
M Protein Assays.
￿
Rabbit sera were tested for type-specific and crossreactive antibodies
by an ELISA as previously reported (3, 16). The presence of opsonic antibodies was detected
by in vitro opsonophagocytosis tests as described (12). Inhibition of opsonization was per-
formed as previously described (12). Indirect bactericidal tests were performed as described (12).
Detection of Heart-crossreactive Antibodies Evoked by pep M19 and SM19(1-24)C
￿
Heart-
crossreactive antibodies evoked by pep M19 or SM19(1-24)C were detected by indirect im-
munofluorescence tests using purified sarcolemmal membranes of human heart tissue (3, 5) .
Inhibition of immunofluorescence was performed as described (5). The specificity of tissue-
crossreactive M protein antibodies was determined using frozen sections (4 gm) of human
skin, lymph node, lung, liver, and kidney.
Affinity Purification of SM19(1-24)C.
￿
Antibodies evoked in rabbits immunized with
SM19(1-24)C were affinity purified over a column of SM19(1-24)C covalently linked to CH-
Sepharose 4B (Pharmacia Inc., Uppsala, Sweden) by methods previously described (10). The
peptide-specific antibodies were eluted from the column with 0.2 M glycine/0.2 M NaCl,
pH 2.8 and were dialyzed overnight against PBS. The eluate was concentrated to the intial
serum volume by membrane ultrafiltration (XM50 membrane; Amicon Corp., Lexington,
MA).
Affinity Purification ofHeart-crossreactive Antibodies.
￿
Heart-crossreactive antibodies evoked by
SM19(1-24)C were adsorbed to and eluted from purified sarcolemmal membranes ofhuman
heart tissue as described previously (3-5). The eluted antibodies were dialyzed overnight against
PBS and concentrated to the initial serum volume by membrane ultrafiltration (XM50 mem-
brane; Amicon Corp.).BRONZE ET AL .
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Immunoblot Analysis.
￿
SDS-PAGE of human myocardium was performed on continuous
gradient gels ranging from 7.5 to 15% polyacrylamide (5) . The electrophoresed proteins were
transferred onto nitrocellulose strips which were incubated in 0.05M Tris/0 .15 M NaCl, pH
7 .5, containing 1% BSA . The strips were incubated overnight with affinity-purified
SM19(1-24)C immune serum diluted 1 :100 . Inhibition experiments were performed by adding
100 ltg/ml of pep M19 or 100 nm/ml of SM19(1-24)C, SM19(1-14)C, or SM19(11-24)C to
the antiserum before the addition ofthe nitrocellulose strips . After an overnight incubation
the strips were extensively washed in 0.05M Tris/0.15 M NaCI/0.05% Tween-20, pH 7.5 .
The strips were incubated with peroxidase-conjugated goat anti-rabbit IgG (Cappel Labora-
tories, Malvern, PA) diluted 1 :2,000 for 2 h at room temperature . After repetitive washings,
the strips . were developed with horseradish peroxidase substrate (Bio-Rad Laboratories) .
Results
Purification and NHZ-Terminal Sequence Analysis of pepM19 .
￿
Pep M19 was purified
from limited peptic digests of intact type 19 streptococci by ammonium sulfate precipi-
tation, ion-exchange chromatography over DEAE cellulose (12), and electroelution
from polyacrylamide gels . The purified protein migrated as a single polypeptide on
SDS-polyacrylamide gel with an apparent molecular weight of 43 x 103 (Fig. 1) .
The NH2-terminal amino acid sequence of the purified protein was determined by
automated Edman degradation (Fig. 2). Analysis of the primary structure by the
method of Chou and Fasman (17) revealed a high a-helical potential beginning at
residue 11 and continuing throughout the remainder of the sequence . Because of
the low a-helical potential ofthe first 10 residues and the proline at position 8, which
is known to be a helix breaker, the first 10 residues are represented as a flexible struc-
ture (Fig . 2) .
Opsonic and Heart-crossreactive Antibodies Evoked by pepM19 .
￿
To determine the im-
munogenicity of pep M19, each of three rabbits was immunized with 100 lig of the
purified protein emulsified in CFA . Immune sera from all three rabbits contained
significant levels of pep M19 antibodies, as determinedbyELISA, and opsonic anti-
FIGURE 1 .
￿
Coomassie blue stain ofSDS-PAGE of the purified pepsin extracted
typ s e 19 streptococcal M protein revealing an apparent molecular weight of 43 x
10 .1852
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FIGURE 2.
￿
Primary structure of the NH2 terminus of pep M19
showing the seven-residue periodicity ofcharged (amino acids in
triangles at position g) and nonpolar residues (amino acids in boxes
and circles at positions a and d, respectively), that predicts an a-
helical three-dimensional structure. The first 10 residues (in ovals)
are represented as a more flexible structure because of the low a-
helical potential and the proline at position 8. The hatched circle
indicates a charged residue at position d.
bodies against type 19 streptococci, as determined by invitroopsonization tests (Table
I). In addition, all three pep M19 antiseracrossreacted with sarcolemmal membranes
ofhumanmyocardium (Table I). Immunofluorescence testsoffrozen sections ofhuman
skin, lymph nodes, lung, liver, and kidney were negative.
Because previous studies have shown that one serotype ofMprotein may contain
epitopes that are shared with heterologous M antigens (5, 16), we assayed the pep
M19 antisera for M protein-crossreactive antibodies by ELISA and opsonization
tests. All three immune sera contained antibodies that crossreacted with pep M5
(with titers of 1,600; 1,600; and 800) and pep M6 (with titers of 3,200; 3,200; and
800), but not with pep M24 (all < 200). The crossreactive antibodies also opsonized
the heterologous serotypesofstreptococci with percent opsonization oftype 5 strep-
tococcirangingbetween 92 and 100and type 6 streptococci between 76 and92. Taken
together, these data show that pep M19 evokes type-specific and crossreactive op-
sonic antibodies, as well as antibodies that crossreact with sarcolemmal membranes
of human myocardium .
Immunogenicity ofan NH2TerminalSynthetic Peptideofpelt M19.
￿
In an effort to iden-
tify protective epitopes ofpep M19 that were not heart crossreactive, we synthesized
peptides copying the NH2 terminus of pep M19 (Fig. 3). To determine the im-
munogenicity ofSM19(1-24)C, rabbits were immunizedwith the unconjugated syn-
thetic peptide emulsified in CFA. All three rabbits developed significant levels of
antibodies against SM19(1-24)C and pep M19, as determined by ELISA (Table II).
TABLE I
Type-specific and Heart-crossreactive Antibodies Evoked in Rabbits Immunized with pep M19
* ELISA titers represent the reciprocal of the highest serum dilution resulting in an OD45o
0.1
1 Percent opsonization equals the percentage of neutrophils with associated streptococci.
§ On a scale of 0 to + + + + .
Antiserum
ELISA titers
against pep M19*
Opsonization
of type 19
streptococci$
Sarcolemmal
immunofluorescence§
Preimmune pool <200 0 0
8104 25,600 92 + + + +
8105 6,400 92 + +
8106 25,600 100 + + +SM19(1-19)C V-R-Y-S-R-E-S-P-E-D-K-L-K-K-C
BRONZE ET AL.
s to is 20
SM19(1-29)C V-R-Y-S-R-E-S-P-E-D-K-L-K-K-I-I-D-D-L-D-A-K-E-N-C
SM19(11-29)C
￿
K-L-K-K-I-I-D-D-L-D-A-K-E-N-C
TABLE II
Immunogenicity of SM19(1-24)C in Rabbits
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FIGURE 3 . Primary structure of
synthetic peptides copying the NH2
terminus o£ pep M19.
All three antisera also opsonized type 19 streptococci. When screened for the pres-
ence of heart-crossreactiveantibodies by indirect immunofluorescence tests, all three
SM19(1-24)C antisera reacted with sarcolemmal membranes of human myocardium
(Table III). Thus, the NH2-terminal 24 residues of pep M19 contain type-specific
opsonic epitopes as well as heart-crossreactive epitopes.
Immunoblot Analysis ofSM19(1-24)C Heart-crossreactive Antibodies.
￿
To identify the
myocardial proteins containing SM19(1-24)C crossreactive epitopes, immunoblot
analyses were performed using SDS-extracted proteins from whole human myocar-
dium that were electrophoresed and transferred to nitrocellulose strips (Fig. 4). The
SM19(1-24)C antiserum reacted with a 60-kD myocardial protein (Fig. 4, lane C).
Inhibition experiments showed that the heart-crossreactive antibodies were completely
inhibited by SM19(1-24)C (lane D), partially inhibited by SM19(1-14)C (lane E),
and totallyinhibited by SM19(11-24)C (lane F) and by the native pep M19 (lane G).
TABLE III
Heart-crossreactive Antibodies Evoked by SM19(1-24)C
Antiserum
ELISA
SM19(1-24)C
titer against:
pep M19
Opsonization
of type 19
streptococci
86126
Prcimmunc <200 <200 4
6 wk 12,800 12,800 100
86127
Prcimmunc <200 <200 8
6 wk 12,800 12,800 80
86128
Prcimmunc <200 <200 4
6 wk 12,800 12,800 88
Immune rabbit serum Sarcolemmal fluorescence
86126
Preimmune 0
6 wk +++
86127
Prcimmunc 0
6 wk ++
86128
Preimmune 0
6 wk +1854
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FIGURE 4 .
￿
Type specificity of heart-crossreactive antibodies evoked
by SM19(1-24)C as determined by immunoblot analysis . SDS-
solubilized human myocardium was electrophoresed under reducing
conditions on an SDS-polyacrylamide continuous gradient gel, ranging
from 7.5 to 15% . Multiple bands were observed in the Coosmassie
blue-stained gel (A) . Immunblot analysis revealed that the preimmune
serum did not react with human myocardial proteins (B), but the
SM19(1-24)C immune serum that had been affinity purified over an
SM19(1-24)C-Sepharose column reacted with a myocardial protein
of an apparent molecular weight of 60 x 10 3 (C). The heart cross-
reactive antibodies were inhibited by SM19(1-24)C (D), SM19(11-24)C
(F), and pep M19 (G), but not SM19(1-14)C (E) .
Crossreactoe Opsonic Epitopes ofSM19(1-24)C
￿
The antisera against SM19(1-24)C
were tested for the presence of crossreactive antibodies against heterologous sero-
types of streptococci by ELISA and in vitro opsonization tests . Two of the three sera
contained significant levels of antibodies against pep M5, but not pep M6 and pep
M24, as determined by ELISA (Table IV) . One of the antisera contained low levels
of opsonic antibodies against type 5 streptococci, indicating the presence of cross-
reactive epitopes exposed on the surface of the organism . To confirm the presence
of type-specific and crossreactive opsonic epitopes on SM19(1-24)C, indirect bac-
tericidal tests were performed (Table V) . The SM19(1-24)C immune serum (rabbit
No. 86127) promoted almost complete killing ofboth type 19 andtype 5 streptococci
during the 3-h rotation in wholeblood . These results were similar to those obtained
with antiserum raised against the native pep M19 antigen (Table V), indicating that
TABLE IV
Type-specific and Crossreactive Antibodies in SM19(1-24)C Immune Sera
Opsonization of:
* Additional serotypes tested that resulted in titers <200 were pep M6 and pep M24 .
1 Results are from assays performed using 10-wk antisera . pep M5 crossreactions were not
observed before 8 wk after the initial injection . Rabbit 86128 died from an injury 7 wk after
immunization .
Immune rabbit
seruml
ELISA
pep M19
titer against :*
pep M5
Type 19
streptococci
Type 5
streptococci
Preimmune pool <200 <200 2 0
86126 12,800 12,800 96 8
86127 12,800 3,200 96 34BRONZE ET AL.
TABLE V
Indirect Bactericidal Activity of SM19(1-24)C Antiserum Against Type 19 and 5 Streptococci
Number of colonies of streptococci surviving
3 h rotation in test mixture
Type 19
￿
Type 5
Antiserum
￿
Inoculum: 49 16 1 60 11 3
Normal rabbit serum
￿
Laked
￿
>2,000
￿
>2,000
￿
Laked
￿
>2,000
￿
400
Anti-SM19(1-24)C
￿
1 0 0 0 0 0
Anti-pep M19
￿
8
￿
0
￿
0
￿
0
￿
0
￿
0
the syntheticpeptide evoked significantlevels ofopsonic antibodies against the homo-
gous type 19 serotype as well as type 5 streptococci.
Todetermine whether SM19(1-24)C shared heart-crossreactive epitopes with pep
M5, we eluted SM19(1-24)C antibodies from sarcolemmal membranes (3, 5) and
assayed for the presence of pep M5-crossreactive antibodies. The affinity-purified
heart-crossreactive antibodies showed an ELISA titerof 1,600 against pep M5, indi-
cating that SM19(1-24)C andpep M5 share atleast one heart-crossreactive epitope.
In an attempt to determine the primary structure ofthe shared epitope, ELISA in-
hibition experimentswere performed by using SM19(1-24)C affinity-purified heart-
crossreactive antibodies reacted with pep M5 and inhibited by synthetic peptides
spanning the entire pep M5 molecule (18); the latter peptides were synthesized for
previous studies (7, 8). None of the synthetic peptides inhibited the crossreactive
antibodies (data not shown), suggesting that the heart-crossreactive epitope that is
shared between pep M5 and SM19(1-24)C was not adequately represented by the
series of synthetic type 5 M protein peptides.
Localization of Opsonic and Heart-crossreactive Epitopes of SM19(1-24)C.
￿
The NH2
terminus ofpepM19 was synthesized in an attempt to evoke protective, but not heart-
crossreactive antibodies againsttype 19streptococci. Having shown that SM19(1-24)C
evoked antibodies of both types, we performed opsonization and immunofluores-
cence inhibition assays using the overlapping subpeptides in order to localize the
type-specific and autoimmune epitopes (Table VI). Opsonization of type 19 strep-
tococci and myocardial immunofluorescence were completely inhibited by pep M19,
SM19(1-24)C, and the subpeptide SM19(11-24)C, but not by SM19(1-14)C (Table
VI). These data indicate that the opsonic and heart-crossreactive epitopes ofSM19
(1-24)C are containedwithin the same limited primary structure ofSM19(11-24)C .
TABLE VI
Localization of Protective and Heart-crossreactive Eptiopes of SM19(1-24)C
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Serum inhibited with:
Opsonization
of type 19
streptococci
Saroclcmmal
fluorescence
Uninhibited 80 + + + +
SM19(1-24)C 0 0
SM19(1-14)C 70 + + +
SM19(11-24)C 4 0
pep M19 0 01856
￿
PROTECTIVE AND HEARTCROSSREACTIVE EPITOPES OF pepM19
Discussion
In the present study we have shown that pep M19 is immunogenic in rabbits and
evokes type-specific and crossreactive opsonic antibodies as well as heart-crossreactive
antibodies. The NH2-terminal primary structure ofpep M19 was determined and
a synthetic peptide copying the first 24-amino acid residues was synthesized.
SM19(1-24)C was immunogenic in rabbits without a carrier protein and evoked
significant levels ofantibodies that reacted with the native pep M19 by ELISA and
opsonic antibodies that reacted with the surface Mprotein ofintact type 19 strep-
tococci. Although our initial goal was to synthesize an immunogen that contained
protective and not tissue-crossreactive epitopes ofpep M19, all three SM19(1-24)C
antisera crossreacted with sarcolemmal membranesofhuman myocardium. Thean-
tibodies specifically recognized a 60-kD myocardial protein, and the crossreactions
were completely inhibited by pep M19, indicating that they were evoked by epitopes
of SM19(1-24)C that were identical to those in the native antigen.
Although we cannot provide definitive evidence that the partial sequence of pep
M19 represents the NH2-terminus of the native molecule, it does have structural
features in common with otherMproteins. The low a-helical potential ofthe initial
sequence, which predicts a more flexible structure is also found in types 1, 5, 6, and
24 Mproteins (18-21). The location ofa proline within the first 11 residues, which
would function as ahelix breaker, is a feature oftypes 1, 5, and 6 Mproteins (18-20)
and now also ofpep M19. Thus, the evidence derived from the structural analysis
of pep M19 suggests that this sequence represents the NH2 terminus of the native
molecule.
Previous studies in ourlaboratory (5) have shown that several Mproteins contain
multiple heart-crossreactive epitopes, some ofwhich are shared by heterologous M
types. Heart-crossreactive antibodies evoked by pep M5 also crossreacted with pep
M6 and pep M19(5). Someofthe pep M5 heart-crossreactive antibodies were specific
for sarcolemmal membrane proteins (8), while others reacted with the heavy chain
ofmyosin (6, 7). Using synthetic peptides copyingthe primary structure ofpep M5
(18), we localized themyosin-crossreactive epitopes topeptide 84-116 (7) and at least
one of the sarcolemmal membrane-crossreactive epitopes to peptide 164-197 (8).
The NH2-terminal synthetic peptides ofpep M5 and pep M6 were shown to con-
tain only type-specific, opsonicepitopes and not tissue-crossreactive epitopes (9-11).
The data presentedhere show forthefirst timethattissue-crossreactive determinants
may be located within the NH2 terminus of M protein molecules.
In thepresent study, SM19(1-24)C evoked heart-crossreactive antibodies that also
reacted with pep M5. A comparison ofthe primary structures ofeach revealed that
residues 12-17 ofpep M19 (LKKIID) were identical to residues 168-173 ofpep M5
(18) (LKKILD), except for a single isoleucine/leucine substitution in the fifth posi-
tion ofthe hexapeptide. The inability of SM5(164-197), which we have previously
showncontains at least one heart-crossreactive epitope (8), to inhibit the SM19(1-24)C
antibodies suggests that the shared hexapeptide either is notpartofthe crossreactive
epitope orthatit isnot presented intheappropriate conformation forantibody binding.
A dodecapeptide copying amino acid residues 12-17 ofpep M19 twice was synthe-
sized, and this peptide did not inhibit the pep M5 crossreactive antibodies evoked
by SM19(1-24)C (ourunpublished data). These datasuggestthatSM19(1-24)C evokesBRONZE ET AL .
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heart-crossreactive antibodies that react with pepM5 epitopes that are at least par-
tially conformational and not adequately predicted by primary structure. In addi-
tion, immunoblot analyses have shown that SM5(164-197)C evokes antibodies that
crossreact with a 40-kD myocardial protein (8), whereas SM19(1-24)C crossreacts
with a 60-kD protein . These findings suggest that the two peptides contain different
heart-crossreactive epitopes .
Previous studies have shown that the NH2-terminal amino acid sequence of sev-
eralMproteins is quite variable from one serotype to another (9-12, 22, 23), whereas
the COOH-terminal sequences are highly conserved (22-24) . TheM protein-cross-
reactive and tissue-crossreactive epitopes of pep M5 are located toward theCOOH
terminus of the molecule (7, 8) . However, in the present study we have shown that
SM19(1-24)C contains potentially harmful tissue-crossreactive epitopes, indicating
that this region ofM protein molecules maynot generally represent an ideal vaccine
component . Nevertheless, synthetic peptides containing heart-crossreactive epitopes
should serve as useful probes to identify myocardial proteins containing crossreac-
tive epitopes . Such studies may provide information regarding the pathogenesis of
acute rheumatic carditis and also eventually may lead to the development of safe
and effective streptococcal vaccines.
Summary
M protein was purified to homogeneity from limited pepsin digests of intact type
19 streptococci (pep M19) . The purified pep M19 when emulsified in CFA and in-
jected into rabbits evoked type-specific and crossreactive opsonic antibodies, as well
as heart-crossreactive antibodies . The NH2-terminal primary structure of pep M19
was determined and a peptide copying the first 24 amino acids [SM19(1-24)C] was
chemically synthesized . Rabbits that were immunized with the unconjugated pep-
tide developed antibodies that recognized thenative pep M19, as determined by ELISA,
and opsonic antibodies against type 19 streptococci, as determined by in vitro op-
sonophagocytosis tests . Thesynthetic peptide also evoked antibodies that crossreacted
with a60-kD sarcolemmal membrane protein ofhuman mycardium . By using over-
lapping synthetic subpeptides as immunoinhibitors, theopsonic and heart-crossreactive
epitopes ofSM19(1-24)C were localized to SM19(11-24)C . Our data confirm the pres-
ence of heart-crossreactive epitopes within the primary structure of pep M19 and
show that these potentially harmful autoimmune epitopes may be located in the
NH2-terminal regions of certain M proteins. We conclude that continued efforts
to identify the primary structures of protective and heart-crossreactive epitopes will
be necessary to elucidate the pathogenesis of acute rheumatic heart disease and to
develop safe and effective streptococcal vaccines .
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